Anti-SARS-CoV-2 Potential of Artemisinins In Vitro
Ruiyuan Cao,Hengrui Hu,Yufeng Li,Xi Wang,Mingyue Xu,Jia Liu,Huanyu Zhang,Yunzheng Yan,Lei Zhao,Wei Li,Tianhong Zhang,Dian Xiao,Xiaojia Guo,Yuexiang Li,Jingjing Yang,Zhihong Hu,Manli Wang,Wu Zhong
DOI: https://doi.org/10.1021/acsinfecdis.0c00522
IF: 5.578
2020-07-31
ACS Infectious Diseases
Abstract:The discovery of novel drug candidates with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) potential is critical for the control of the global COVID-19 pandemic. Artemisinin, an old antimalarial drug derived from Chinese herbs, has saved millions of lives. Artemisinins are a cluster of artemisinin-related drugs developed for the treatment of malaria and have been reported to have multiple pharmacological activities, including anticancer, antiviral, and immune modulation. Considering the reported broad-spectrum antiviral potential of artemisinins, researchers are interested in whether they could be used to combat COVID-19. We systematically evaluated the anti-SARS-CoV-2 activities of nine artemisinin-related compounds <i>in vitro</i> and carried out a time-of-drug-addition assay to explore their antiviral mode of action. Finally, a pharmacokinetic prediction model was established to predict the therapeutic potential of selected compounds against COVID-19. Arteannuin B showed the highest anti-SARS-CoV-2 potential with an EC<sub>50</sub> of 10.28 ± 1.12 μM. Artesunate and dihydroartemisinin showed similar EC<sub>50</sub> values of 12.98 ± 5.30 μM and 13.31 ± 1.24 μM, respectively, which could be clinically achieved in plasma after intravenous administration. Interestingly, although an EC<sub>50</sub> of 23.17 ± 3.22 μM was not prominent among the tested compounds, lumefantrine showed therapeutic promise due to high plasma and lung drug concentrations after multiple dosing. Further mode of action analysis revealed that arteannuin B and lumefantrine acted at the post-entry step of SARS-CoV-2 infection. This research highlights the anti-SARS-CoV-2 potential of artemisinins and provides leading candidates for anti-SARS-CoV-2 drug research and development.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsinfecdis.0c00522?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00522</a>.Detailed methods and results of PBPK modeling (<a class="ext-link" href="/doi/suppl/10.1021/acsinfecdis.0c00522/suppl_file/id0c00522_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
chemistry, medicinal,infectious diseases